At what estimated glomerular filtration rate (eGFR) should metformin be dose‑reduced or discontinued and empagliflozin (Jardiance) be continued or stopped?

eGFR Thresholds for Metformin and Empagliflozin Management

Metformin: eGFR-Based Dosing Algorithm

Metformin should be discontinued when eGFR falls below 30 mL/min/1.73 m², while empagliflozin can be continued down to eGFR ≥20 mL/min/1.73 m² for cardiovascular and renal protection. 1

eGFR ≥60 mL/min/1.73 m²

• Continue standard metformin dosing (up to 2000–2550 mg daily) without dose reduction 1
• Monitor eGFR at least annually 1
• No restrictions on empagliflozin use 2

eGFR 45–59 mL/min/1.73 m² (CKD Stage 3a)

• Continue current metformin dose without mandatory reduction in most patients 1
• Consider dose reduction in elderly patients or those with liver disease, alcoholism, or heart failure 1
• Increase eGFR monitoring frequency to every 3–6 months 1
• Empagliflozin 10 mg daily can be initiated or continued 2

eGFR 30–44 mL/min/1.73 m² (CKD Stage 3b)

• Reduce metformin dose by 50% to a maximum of 1000 mg daily (e.g., 500 mg twice daily) 1
• Do not initiate metformin in patients not already on therapy 1
• Monitor eGFR every 3–6 months 1
• Carefully reassess benefit-risk balance, especially in frail or comorbid patients 1
• Empagliflozin 10 mg daily can be continued or initiated 2

eGFR <30 mL/min/1.73 m² (CKD Stage 4–5)

• Discontinue metformin immediately—this is an absolute contraindication 1
• Risk of metformin-associated lactic acidosis becomes unacceptably high with hazard ratio of 1.97 (95% CI 1.03–3.77) 3
• Empagliflozin can be continued down to eGFR ≥20 mL/min/1.73 m² for cardiovascular and renal protection 2
• Do not initiate empagliflozin if eGFR <20 mL/min/1.73 m² 2

---

Empagliflozin: eGFR-Based Management

Empagliflozin has a significantly broader renal safety profile than metformin and provides cardiovascular and renal benefits independent of glucose lowering. 2

Key Thresholds

• Can be initiated when eGFR ≥20 mL/min/1.73 m² 2
• Should be continued even as eGFR declines below 45 mL/min/1.73 m², as the EMPA-KIDNEY trial demonstrated a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72,95% CI 0.64–0.82) across all eGFR ranges including patients with eGFR 20–45 mL/min/1.73 m² 2
• Benefits are consistent in patients with or without diabetes 2
• Reduces hospitalization from any cause (HR 0.86,95% CI 0.78–0.95) 2

Practical Considerations

• Empagliflozin causes an acute, reversible decrease in eGFR within the first week—this is not an indication to discontinue therapy 4
• Assess and correct volume depletion before initiating 4
• Counsel patients about symptoms of volume depletion and hypotension 4

---

Critical Situations Requiring Temporary Metformin Discontinuation

Hold metformin immediately in the following scenarios, regardless of baseline eGFR: 1

• Acute illness causing volume depletion (sepsis, severe diarrhea, vomiting, dehydration)
• Hospital admission with elevated acute kidney injury risk
• Acute decompensated heart failure with hypoperfusion
• Before iodinated contrast imaging in patients with eGFR 30–60 mL/min/1.73 m² or those with liver disease, alcoholism, or heart failure
• Re-measure eGFR 48 hours after contrast before restarting metformin 1

---

Alternative Glucose-Lowering Therapies When Metformin Must Be Discontinued

First-Line (eGFR <30 mL/min/1.73 m²)

• GLP-1 receptor agonists with proven cardiovascular benefits (dulaglutide, liraglutide, semaglutide) 1
• Dulaglutide can be used down to eGFR >15 mL/min/1.73 m² without dose adjustment 1

Second-Line

• DPP-4 inhibitors with renal dose adjustment 1
  • Sitagliptin: 25 mg daily when eGFR <30 mL/min/1.73 m²
  • Linagliptin: no dose adjustment required at any eGFR level

Third-Line

• Insulin therapy becomes primary option in Stage 5 CKD, with 25–50% dose reduction as eGFR declines below 30 mL/min/1.73 m² due to prolonged insulin half-life 1

---

Additional Monitoring Requirements

• Vitamin B12 levels should be checked in patients on metformin for >4 years, as approximately 7% develop deficiency 1
• Use eGFR, not serum creatinine alone, to guide metformin decisions—creatinine-based cutoffs are outdated and lead to inappropriate discontinuation, especially in elderly or small-statured patients 1, 5
• Population studies show metformin use at eGFR 45–60 mL/min/1.73 m² is associated with reduced mortality compared to other glucose-lowering therapies 1, 3

---

Common Pitfalls to Avoid

• Do not discontinue metformin prematurely at eGFR 45–59 mL/min/1.73 m²—this range is well above the cessation threshold 1
• Do not rely solely on serum creatinine—always calculate eGFR, as males with creatinine 130–150 μmol/L may have eGFR 30–59 mL/min/1.73 m², while females with the same creatinine often have lower eGFR 5, 6
• Do not stop empagliflozin when eGFR drops below 45 mL/min/1.73 m²—unlike older guidance for dapagliflozin, empagliflozin provides continued benefit down to eGFR ≥20 mL/min/1.73 m² 2
• Failing to adjust metformin dose proportionally as eGFR declines increases risk of drug accumulation 1